ARTG Entry
SEEBRI
ARTG entry for SEEBRI (glycopyrronium), ARTG 191517 — Product Information, dosage form, registration history. Compiled by arcimedes.
- Sponsor: Novartis Pharmaceuticals
- Active ingredient: glycopyrronium
- Therapeutic area: Respiratory
I appreciate the detailed instructions, but
I must respectfully note a significant mismatch in the source documents provided.
The documents contain information about **two different pharmaceutical products**:
1. **Document 1** ("SEEBRI (latest variant)") describes **Axhidrox** — a topical cream containing glycopyrronium bromide for axillary hyperhidrosis (excessive underarm sweating).
2. **Documents 2–4** describe **SEEBRI BREEZHALER** — a powder for inhalation containing glycopyrronium bromide for chronic obstructive pulmonary disease (COPD).
These are distinct medicines with different formulations, routes of administration, indications, and dosing regimens. They cannot be combined into a single Brand Dossier.
**To proceed, I need clarification:** — Should the dossier be for **SEEBRI BREEZHALER** (the inhalation powder for COPD)? If so, Document 1 (Axhidrox cream) is not applicable. — Or should it be for **Axhidrox** (the topical cream for hyperhidrosis)? If so, Documents 2–4 are not applicable.
Please confirm which medicine should be documented, and I will produce the Brand Dossier with proper citations to the relevant sources only.